Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of trends in the proportion of Phase II and Phrase III in commercial oncology clinical trials.

The Department holds data on commercial clinical trials by phase and therapeutic area, including oncology. However, we do not routinely assess trends in specific segments such as Phase II and Phase III oncology clinical trials.

We use this information alongside wider intelligence to inform policy and to support a competitive environment for clinical research across all phases and disease areas, underpinned by significant investment in National Institute for Health and Care Research delivery infrastructure.